Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
Biomea Fusion will report results from its Phase I GLP-131 study of BMF-650, an oral small-molecule GLP-1 receptor agonist, on Tuesday, October 13, 2026. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the data, with a replay available on the company website.
Key figures
- Drug Name
- BMF-650
- Phase Of Trial
- Phase I
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.